Learn when free testosterone adds context to total testosterone, how SHBG matters, and why the measurement method affects interpretation.
Total testosterone and free testosterone offer different views of circulating hormone, and the clinical question is whether the free result helps clarify suspected testosterone deficiency when the total result or its protein-binding context is uncertain.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret hormone results and make individual testing or treatment decisions.
Total testosterone, often shortened to TT, describes the overall testosterone circulating in blood. Its clinical role is to provide a starting measurement when a clinician assesses possible testosterone deficiency. It is not a diagnosis by itself.
The European Association of Urology (EAU) guideline describes diagnosis of late-onset hypogonadism as requiring compatible signs and symptoms alongside low morning total testosterone. The low result should be confirmed on at least two occasions under fasting conditions with a reliable assay. This framework explains why an isolated low reading does not settle the question.
Testostra's guide to why an initial low result needs confirmation provides further context for that part of the assessment.
Total testosterone varies with sex hormone-binding globulin, or SHBG. This protein binds testosterone in circulation. When SHBG is substantially high or low, total testosterone alone may provide a less complete picture of androgen availability.
That does not make total testosterone an inferior test. It means the result answers one part of the clinical question while leaving protein binding to be considered separately. A clinician may need both pieces to understand an uncertain result.
The EAU guideline identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also says standardised automated platform immunoassays for total testosterone correlate well with LC-MS/MS. The assay question therefore needs to be specific to what is being measured.
The guideline reports a survey across 27 European countries that found variation in laboratory practices. Findings included limited adoption of LC-MS/MS and inconsistent procedures before sample analysis. It also notes that commercial immunoassay reference ranges may lack clear information about the reference population and sampling quality.
For the reader, the useful distinction is between a number and the testing process behind it. A total testosterone result belongs with its sampling conditions and laboratory context rather than being treated as a stand-alone verdict.
Free testosterone, often shortened to fT, refers to testosterone that is not bound to circulating proteins. It describes a different part of the same hormone picture rather than a separate hormone. Its clinical value lies in whether that additional view resolves uncertainty.
The EAU guideline says free-testosterone evaluation can improve diagnostic accuracy in symptomatic men, particularly older men with obesity. It also recommends considering it when a clinical condition may alter SHBG. These are targeted reasons to add information rather than reasons to replace total testosterone testing for everyone.
The important distinction is not simply total versus free. It is total testosterone interpreted in context versus additional free-testosterone information obtained through an appropriate method.
The EAU guideline identifies equilibrium dialysis as the most accurate method for measuring free testosterone. This is a direct measurement approach rather than a mathematical estimate.
Its place in the comparison is straightforward: when discussing the accuracy of a measured free-testosterone result, equilibrium dialysis is the method the guideline identifies as most accurate. A report's test name should therefore be read alongside its method rather than assumed to describe how the number was obtained.
The guideline describes calculated free testosterone using serum SHBG and albumin as an alternative. The calculation provides an estimate rather than directly measuring the unbound fraction.
That distinction matters because the estimate depends on its inputs and the calculation used. A calculated result should not be treated as automatically interchangeable with a result obtained by equilibrium dialysis. Understanding the approach is part of understanding the result.
For more detail on that distinction, Testostra explains how calculation choices shape the estimate.
The EAU guideline cautions that available immunoassays do not accurately estimate free testosterone and advises against direct free-testosterone evaluation using them. This warning concerns free-testosterone testing specifically. It should not be confused with the guideline's separate assessment of standardised automated immunoassays for total testosterone.
A result labelled “direct free testosterone” therefore needs its method identified before its reliability can be judged. The word “direct” is not itself evidence of accuracy.
The broader lesson is to distinguish the reported quantity from the laboratory approach. Testostra's explanation of differences between free-testosterone test methods develops that comparison further.
The interaction between total testosterone and free testosterone becomes most useful when SHBG changes the interpretation. The EAU guideline strongly recommends measuring SHBG and calculating free testosterone in conditions characterised by altered SHBG.
This is not a contest in which one hormone number automatically defeats another. The clinical task is to understand how the overall concentration relates to protein binding and whether the resulting picture fits the man's symptoms.
The guideline lists several factors associated with changes in SHBG. Examples include:
Its wider list also includes medications and other medical conditions. These associations give clinicians reasons to consider binding context; they do not turn an SHBG result into proof of hypogonadism.
Thyroid conditions illustrate the distinction clearly. The guideline associates hyperthyroidism with increased SHBG and hypothyroidism with decreased SHBG. Simply knowing that a thyroid condition exists is less informative than understanding the specific clinical context.
The same principle applies to obesity. The guideline identifies it as a condition associated with decreased SHBG while also highlighting older symptomatic men with obesity as a group in whom free-testosterone evaluation may improve diagnostic accuracy.
For a closer look at this relationship, Testostra explains why SHBG can change the meaning of a total result.
When total testosterone is near a clinical decision boundary, the question is whether more information would meaningfully clarify its interpretation. The research supports discussing SHBG and free testosterone in that setting rather than treating free testosterone as an automatic tie-breaker.
A useful comparison keeps the purpose of each result visible. Total testosterone supplies the overall circulating measurement. SHBG provides binding context. A suitably obtained free-testosterone result adds another view that the clinician can weigh alongside the clinical assessment.
This avoids a common interpretive shortcut: treating whichever number appears more concerning as the final answer. A disagreement between results is a reason to examine the testing context rather than choose a preferred result without that review.
The EAU guideline says 220 pmol/L (6.4 ng/dL) may be considered as a free-testosterone threshold in altered-SHBG settings. It explicitly describes the supporting evidence as limited. That figure is not presented as a definitive boundary for every man or every testing situation.
The practical implication is to ask how a threshold applies to the particular clinical question and laboratory method. A number used in an altered-SHBG assessment should not be detached from that setting and applied as a universal rule.
A clinician-led discussion can make the comparison more concrete without turning it into a self-diagnosis exercise. Useful questions include:
These questions keep the focus on what the additional test contributes. They also distinguish a request for more information from an assumption that a particular result must establish testosterone deficiency.
The goal is not to collect competing hormone numbers. It is to identify whether the additional measurement answers an unresolved clinical question and gives the clinician a more coherent basis for interpretation.
Total testosterone provides the starting measurement, while SHBG and appropriately assessed free testosterone add context that belongs within the same symptom-based clinical evaluation.
The clinician assessing an uncertain testosterone panel remains responsible for medical decisions, with Testostra making the underlying biomarker concepts more accessible. Its reporting helps men understand why total testosterone, free testosterone and SHBG belong in the same conversation rather than treating one laboratory value as a complete answer.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra